Les nouvelles applications comprennent Veeva LIMS Basics et PromoMats Basics pour favoriser la rapidité et la croissance BARCELONE, Espagne, 6 novembre 2025 /PRNewswire/ — Veeva Systems (NYSE : VEEV) a annoncé aujourd’hui que plus de 100 entreprises de biotechnologie ont choisi Veeva Basics pour développer les opérations dans les domaines clinique, réglementaire et de la qualité.… Continue reading Veeva Basics adopté par plus de 100 entreprises de biotechnologie émergentes pour simplifier et standardiser les opérations
Author: PR Newswire Online News
SNPS Investors Have Opportunity to Lead Synopsys, Inc. Securities Fraud Lawsuit
NEW YORK, Nov. 5, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers and acquirers of Synopsys, Inc. (NASDAQ: SNPS) securities between December 4, 2024 and September 9, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has… Continue reading SNPS Investors Have Opportunity to Lead Synopsys, Inc. Securities Fraud Lawsuit
Sky Labs attrae investimenti con la sussidiaria Omron ‘OMRON VENTURES’
Il numero 1 nel monitoraggio della pressione sanguigna a livello mondiale OMRON Healthcare firma un memorandum d’intesa per una partnership strategica SEOUL, Corea del Sud, 5 novembre 2025 /PRNewswire/ — Il 4 novembre 2025, Sky Labs ha annunciato di aver attirato investimenti con OMRON Ventures(OVC: Minato-ku, Tokyo), il capitale di rischio aziendale (CVC) del Gruppo Omron. Ciò… Continue reading Sky Labs attrae investimenti con la sussidiaria Omron ‘OMRON VENTURES’
Evommune Announces Pricing of its Initial Public Offering
PALO ALTO, Calif., Nov. 5, 2025 /PRNewswire/ — Evommune, Inc. (“Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced the pricing of its initial public offering of 9,375,000 shares of common stock at an initial public offering price of $16.00 per share. In addition, Evommune has… Continue reading Evommune Announces Pricing of its Initial Public Offering
The World’s First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
CorrectSequence Therapeutics’ CS-121 Completed Dosing of First Chylomicronemia Patient, Demonstrating Excellent Safety and Significant Efficacy SHANGHAI, Nov. 5, 2025 /PRNewswire/ — On November 6, 2025, Shanghai, China, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, announced that the first patient in its Investigator-Initiated Trial (IIT) of the base-editing therapy CS-121… Continue reading The World’s First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
GOFO Joins Walmart Marketplace Logistics Network, Enabling Faster, Surcharge-Free Peak Season Deliveries
The Integration gives Walmart Marketplace sellers access to GOFO’s nationwide delivery network, enabling faster, more reliable, and fully transparent last-mile delivery without peak-season surcharges. LOS ANGELES, Nov. 5, 2025 /PRNewswire/ — GOFO today announced its integration with Walmart Marketplace, offering sellers nationwide last-mile coverage, faster SLAs, and real-time visibility. The partnership also builds strong operational… Continue reading GOFO Joins Walmart Marketplace Logistics Network, Enabling Faster, Surcharge-Free Peak Season Deliveries
Metsera Issues Statement in Response to Litigation Ruling
NEW YORK, Nov. 5, 2025 /PRNewswire/ — Metsera, Inc. (NASDAQ: MTSR) (“Metsera” or the “Company”) today issued the following statement in response to a ruling in the litigation filed against the Company by Pfizer: “Metsera is gratified by the Delaware Court of Chancery’s decision to deny Pfizer’s request for a temporary restraining order to block… Continue reading Metsera Issues Statement in Response to Litigation Ruling
Berger Montague PC Investigating Claims on Behalf of Fiserv, Inc. (NYSE: FI) Investors After Class Action Filing
PHILADELPHIA, Nov. 5, 2025 /PRNewswire/ — National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit against Fiserv, Inc. (NYSE: FI) (“Fiserv” or the “Company”) has been filed on behalf of investors who purchased Fiserv shares during the period of July 23, 2025 through October 29, 2025 (the “Class Period”). Investor Deadline: Investors who purchased… Continue reading Berger Montague PC Investigating Claims on Behalf of Fiserv, Inc. (NYSE: FI) Investors After Class Action Filing
Lawproactive Launches Next-Generation CRM, Marrying Data and Location with Geo-Optimized Funnels for Attorney Lead Generation
The all-new Lawproactive system introduces a proprietary platform that cuts wasted ad spend and delivers highly qualified, local leads to law firms by mastering Generative Engine Optimization (GEO). REDONDO BEACH, Calif., Nov. 5, 2025 /PRNewswire/ — Lawproactive today announced the launch of its revolutionary new Lawproactive CRM system, a solution engineered specifically for the legal… Continue reading Lawproactive Launches Next-Generation CRM, Marrying Data and Location with Geo-Optimized Funnels for Attorney Lead Generation
The World’s First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
CorrectSequence Therapeutics’ CS-121 Completed Dosing of First Chylomicronemia Patient, Demonstrating Excellent Safety and Significant Efficacy SHANGHAI, Nov. 5, 2025 /PRNewswire/ — On November 6, 2025, Shanghai, China, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, announced that the first patient in its Investigator-Initiated Trial (IIT) of the base-editing therapy CS-121… Continue reading The World’s First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia